JP2011037891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011037891A5 JP2011037891A5 JP2010233467A JP2010233467A JP2011037891A5 JP 2011037891 A5 JP2011037891 A5 JP 2011037891A5 JP 2010233467 A JP2010233467 A JP 2010233467A JP 2010233467 A JP2010233467 A JP 2010233467A JP 2011037891 A5 JP2011037891 A5 JP 2011037891A5
- Authority
- JP
- Japan
- Prior art keywords
- grams
- ophthalmic composition
- aqueous ophthalmic
- gly
- asp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims 40
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims 34
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 27
- 229920002678 cellulose Polymers 0.000 claims 22
- 239000001913 cellulose Substances 0.000 claims 22
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 claims 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 16
- 108700016464 N-acetylcarnosine Proteins 0.000 claims 15
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 13
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 13
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 13
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 13
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 13
- 208000030533 eye disease Diseases 0.000 claims 9
- 210000001742 aqueous humor Anatomy 0.000 claims 8
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims 8
- 235000011187 glycerol Nutrition 0.000 claims 8
- 238000010521 absorption reaction Methods 0.000 claims 7
- 239000008367 deionised water Substances 0.000 claims 7
- 229910021641 deionized water Inorganic materials 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 7
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 7
- 239000011736 potassium bicarbonate Substances 0.000 claims 7
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 7
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 6
- 108010087806 Carnosine Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 6
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims 5
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 5
- 230000000903 blocking effect Effects 0.000 claims 5
- -1 polyoxyethylene Polymers 0.000 claims 5
- 230000008719 thickening Effects 0.000 claims 5
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 4
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 239000000314 lubricant Substances 0.000 claims 4
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 210000004087 cornea Anatomy 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000007905 drug manufacturing Methods 0.000 claims 3
- 231100000040 eye damage Toxicity 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 3
- 229960003080 taurine Drugs 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 108010063045 Lactoferrin Proteins 0.000 claims 2
- 102100032241 Lactotransferrin Human genes 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 229960004050 aminobenzoic acid Drugs 0.000 claims 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 2
- 229940078795 lactoferrin Drugs 0.000 claims 2
- 235000021242 lactoferrin Nutrition 0.000 claims 2
- 238000005461 lubrication Methods 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 235000019833 protease Nutrition 0.000 claims 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010068906 Computer vision syndrome Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 206010015946 Eye irritation Diseases 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 206010057436 Vitreous injury Diseases 0.000 claims 1
- 208000034700 Vitreous opacities Diseases 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 208000003464 asthenopia Diseases 0.000 claims 1
- 229940000635 beta-alanine Drugs 0.000 claims 1
- 230000036983 biotransformation Effects 0.000 claims 1
- 229910021538 borax Inorganic materials 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 229940085237 carbomer-980 Drugs 0.000 claims 1
- 229940096529 carboxypolymethylene Drugs 0.000 claims 1
- 229940044199 carnosine Drugs 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 208000021921 corneal disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 231100000013 eye irritation Toxicity 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 229940067107 phenylethyl alcohol Drugs 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 claims 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 201000010041 presbyopia Diseases 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 235000010339 sodium tetraborate Nutrition 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41435702P | 2002-09-30 | 2002-09-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004539362A Division JP2006504701A (ja) | 2002-09-30 | 2003-09-29 | 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011037891A JP2011037891A (ja) | 2011-02-24 |
| JP2011037891A5 true JP2011037891A5 (https=) | 2012-07-12 |
Family
ID=32043384
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004539362A Pending JP2006504701A (ja) | 2002-09-30 | 2003-09-29 | 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段 |
| JP2010233467A Pending JP2011037891A (ja) | 2002-09-30 | 2010-10-18 | 薬剤組成物の製造のための水性眼科用組成物の使用、及び水性眼科用組成物 |
| JP2010233468A Pending JP2011037892A (ja) | 2002-09-30 | 2010-10-18 | 治療手段 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004539362A Pending JP2006504701A (ja) | 2002-09-30 | 2003-09-29 | 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010233468A Pending JP2011037892A (ja) | 2002-09-30 | 2010-10-18 | 治療手段 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US7795203B2 (https=) |
| EP (1) | EP1551399A4 (https=) |
| JP (3) | JP2006504701A (https=) |
| WO (1) | WO2004028536A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050112113A1 (en) * | 2000-08-16 | 2005-05-26 | Till Jonathan S. | Presbyopia treatment by lens alteration |
| US8147816B2 (en) | 2000-08-16 | 2012-04-03 | Encore Health, Llc | Presbyopia treatment by lens alteration |
| US8647612B2 (en) | 2008-03-05 | 2014-02-11 | Encore Health, Llc | Dithiol compounds, derivatives, and treatment of presbyopia |
| US7935332B2 (en) | 2000-08-16 | 2011-05-03 | Encore Health, Llc | Presbyopia treatment by lens alteration |
| US8697109B2 (en) | 2000-08-16 | 2014-04-15 | Encore Health, Llc | Caged mercaptan and seleno-mercaptan compounds and methods of using them |
| US7914815B2 (en) | 2000-08-16 | 2011-03-29 | Encore Health, Llc | Method for delivery of pharmaceuticals for treating or preventing presbyopia |
| US7795203B2 (en) * | 2002-09-30 | 2010-09-14 | Babizhayev Mark A | Method for topical treatment of eye disease and composition and device for said treatment |
| NZ540885A (en) * | 2002-12-20 | 2009-02-28 | Chakshu Res Inc | Ophthalmic formulation for the prevention and treatment of ocular conditions |
| WO2004064866A1 (ja) * | 2003-01-20 | 2004-08-05 | Innovative Vision Products, Inc. | カルノシナーゼ阻害剤とｌ−カルノシン類との併用および組成物 |
| EP1761272B1 (en) | 2004-06-08 | 2013-04-24 | Flamma S.P.A. | Compositions containing d-carnosine |
| JP2006131580A (ja) * | 2004-11-09 | 2006-05-25 | Rohto Pharmaceut Co Ltd | 粘膜適用組成物 |
| US8569367B2 (en) | 2004-11-16 | 2013-10-29 | Allergan, Inc. | Ophthalmic compositions and methods for treating eyes |
| KR101484499B1 (ko) | 2005-02-14 | 2015-01-20 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | 안과용 렌즈의 제조방법, 안과용 장치 및 콘택트 렌즈 |
| TW200722109A (en) * | 2005-03-31 | 2007-06-16 | Bausch & Lomb | Polysaccharide and polyol composition for treating dry eye and related methods of manufacture and methods of use |
| TWI393567B (zh) * | 2005-03-31 | 2013-04-21 | Bausch & Lomb | 治療乾眼之組合物及相關之製造方法及使用方法 |
| US9052529B2 (en) | 2006-02-10 | 2015-06-09 | Johnson & Johnson Vision Care, Inc. | Comfortable ophthalmic device and methods of its production |
| US7776364B2 (en) | 2006-03-24 | 2010-08-17 | Advanced Scientific, Llc | Non-surgical method for treating cataracts in mammals including man |
| US20120122815A1 (en) * | 2006-03-28 | 2012-05-17 | Erning Xia | Composition for Treating Dry Eye and Related Methods of Manufacture and Methods of Use |
| JP5302546B2 (ja) * | 2008-02-12 | 2013-10-02 | 雪印メグミルク株式会社 | 白内障予防剤 |
| US9044439B2 (en) | 2008-03-05 | 2015-06-02 | Encore Health, Llc | Low dose lipoic and pharmaceutical compositions and methods |
| WO2009111635A2 (en) | 2008-03-05 | 2009-09-11 | Encore Health, Llc | Dithiol compounds, derivatives, and uses therefor |
| NL2002214C2 (en) * | 2008-11-17 | 2010-05-18 | Louis Johan Wagenaar | Contact lens care solution. |
| US9308070B2 (en) | 2008-12-15 | 2016-04-12 | Allergan, Inc. | Pliable silk medical device |
| US20110111031A1 (en) * | 2009-04-20 | 2011-05-12 | Guang-Liang Jiang | Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| EP3069612A3 (en) | 2009-06-15 | 2016-10-19 | Encore Health, LLC | Dithiol compounds, derivatives, and uses therefor |
| EP2821405B1 (en) | 2009-06-15 | 2016-04-13 | Encore Health, LLC | Choline esters for treating presbyopia and cataract |
| CA2777827C (en) | 2009-10-30 | 2020-08-18 | Retrotope, Inc. | Alleviating oxidative stress disorders with pufa derivatives |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| EP3689342A1 (en) | 2011-04-26 | 2020-08-05 | Retrotope, Inc. | Oxidative retinal diseases |
| AU2012249917B2 (en) | 2011-04-26 | 2017-06-15 | Biojiva Llc | Neurodegenerative disorders and muscle diseases implicating PUFAs |
| AU2012249918B2 (en) | 2011-04-26 | 2017-06-15 | Biojiva Llc | Impaired energy processing disorders and mitochondrial deficiency |
| AU2012249920B2 (en) | 2011-04-26 | 2017-06-15 | Biojiva Llc | Disorders implicating PUFA oxidation |
| US8957048B2 (en) | 2011-10-06 | 2015-02-17 | Allergan, Inc. | Compositions for the treatment of dry eye |
| US9907826B2 (en) | 2011-12-07 | 2018-03-06 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
| CA2858574C (en) | 2011-12-07 | 2017-05-30 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
| EP2941128B1 (en) | 2012-12-20 | 2023-06-28 | Rajiv Bhushan | Antimicrobial compositions |
| CN105189531B (zh) | 2013-03-13 | 2020-02-21 | 安特易斯有限公司 | 用于皮肤复新的肽及其使用方法 |
| EP4137139A1 (en) | 2013-07-10 | 2023-02-22 | Matrix Biology Institute | Compositions of hyaluronan with high elasticity and uses thereof |
| US9265809B2 (en) | 2013-10-09 | 2016-02-23 | Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
| CA2941518A1 (en) * | 2014-03-03 | 2015-09-11 | Encore Vision, Inc. | Lipoic acid choline ester compositions and methods of use |
| ES2632808T3 (es) | 2014-09-04 | 2017-09-15 | Nicox Science Ireland | Compuestos de carnosina donadores de óxido nítrico |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| US12472157B2 (en) | 2014-11-07 | 2025-11-18 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
| NZ732058A (en) | 2014-11-25 | 2023-06-30 | Allergan Inc | Stabilized omega-3 ophthalmic compositions |
| KR101690539B1 (ko) | 2015-07-30 | 2016-12-29 | 주식회사 아이바이오코리아 | 건성안 예방 또는 치료용 약학조성물 |
| PL3352766T3 (pl) | 2015-09-24 | 2021-08-02 | Matrix Biology Institute | Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia |
| ES3007759T3 (en) | 2015-09-28 | 2025-03-20 | Azura Ophthalmics Ltd | Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion |
| CA3005983A1 (en) | 2015-11-23 | 2017-06-01 | Retrotope, Inc. | Site-specific isotopic labeling of 1,4-diene systems |
| CN108601763A (zh) * | 2016-02-22 | 2018-09-28 | 参天制药株式会社 | 含有多佐胺和溴莫尼定的药物组合物 |
| US20190038555A1 (en) * | 2016-02-26 | 2019-02-07 | The Regents Of The University Of California | Bicontinuous microemulsions and methods of use thereof |
| CN114469991A (zh) | 2016-04-14 | 2022-05-13 | 阿祖拉眼科有限公司 | 用于治疗睑板腺功能障碍的二硫化硒组合物 |
| CN110167516B (zh) | 2017-01-31 | 2022-08-30 | 金伯利-克拉克环球有限公司 | 包含苯甲酸酯的抗细菌组合物及利用该组合物抑制细菌生长的方法 |
| CN112516080B (zh) * | 2018-01-23 | 2023-09-19 | 盛元医药广州有限公司 | 一种眼用药物组合物及其制备方法和应用 |
| US11077150B2 (en) * | 2018-10-09 | 2021-08-03 | Massoumeh Kharazmi | Methods and compositions for treatment of eye conditions |
| CN113226349A (zh) | 2018-10-19 | 2021-08-06 | 激流生物科学有限公司 | 抗微生物肽及其使用方法 |
| WO2020146660A1 (en) | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
| EP3908341A4 (en) | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
| EP3908271A4 (en) | 2019-01-11 | 2022-10-26 | NaCuity Pharmaceuticals, Inc. | N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT |
| US20220272987A1 (en) * | 2019-04-12 | 2022-09-01 | Jeffrey H. ROBBINS | Composition including effervescent agents, biostimulant, nutrient, and pesticide |
| CA3166357A1 (en) | 2020-01-10 | 2021-07-15 | Azura Ophthalmics Ltd. | Instructions for composition and sensitivity |
| CA3172351A1 (en) | 2020-02-21 | 2021-08-26 | Retrotope, Inc. | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| EP4346720A4 (en) | 2021-05-28 | 2025-01-01 | Sight Sciences, Inc. | INTRAOCULAR DEVICES, SYSTEMS AND METHODS |
| US20260096978A1 (en) * | 2022-09-19 | 2026-04-09 | Symrise Ag | A method for preventing, mitigating and/or treating ptgs2-induced skin disorders and related dysfunctions |
| KR102513994B1 (ko) * | 2022-10-26 | 2023-03-24 | 김태윤 | 반려동물의 눈물 착색예방용 조성물 |
| WO2024135853A1 (ja) | 2022-12-23 | 2024-06-27 | Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 | 間葉系幹細胞又はその培養上清の利用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL188266C (nl) * | 1975-07-29 | 1992-05-18 | Merck & Co Inc | Werkwijze ter bereiding van een oogheelkundig inplantaat. |
| CA1141663A (en) * | 1979-09-06 | 1983-02-22 | Yukihisa Ishii | Ophthalmic solution for intraocular pressure adjustment |
| US4248882A (en) * | 1980-02-12 | 1981-02-03 | Pfizer Inc. | Treating diabetes-associated complications with hydantoin amines |
| JPS57108072A (en) | 1980-12-18 | 1982-07-05 | Ajinomoto Co Inc | Preparation of n-acylcarnosine |
| JPS57203440A (en) * | 1981-06-11 | 1982-12-13 | Nihon Contact Lens Seizou Kk | Treating tool |
| US4722933A (en) * | 1985-12-20 | 1988-02-02 | Nelson Research & Development Co. | Substituted 2-aminotetralins |
| US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US4771036A (en) * | 1986-02-10 | 1988-09-13 | Trustees Of Columbia University In The City Of New York | Method and ophthalmic composition for the prevention and reversal of cataracts |
| JPS6471822A (en) * | 1987-09-12 | 1989-03-16 | Rohto Pharma | Ophthalmic sustained release preparation |
| US5496820A (en) | 1988-10-20 | 1996-03-05 | Peraelampi; Markku | Ophthalmic use of S-timolol hemihydrate |
| US5192785A (en) * | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
| US5192743A (en) * | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
| IT1260467B (it) | 1992-01-29 | 1996-04-09 | Bruschettini Srl | Medicamento contenente arg-gly-asp per il trattamento del glaucoma |
| JPH06211665A (ja) * | 1993-01-19 | 1994-08-02 | Rohto Pharmaceut Co Ltd | ジラゼプを必須成分とする眼圧降下剤 |
| FR2701948B1 (fr) * | 1993-02-22 | 1996-07-26 | Exsymol Sa | Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires. |
| RU2100020C1 (ru) | 1993-06-23 | 1997-12-27 | Лейрас Ой | Средство для местного лечения глазной гипертензии и глаукомы и способ его получения |
| CA2125060C (en) * | 1993-07-02 | 1999-03-30 | Henry P. Dabrowski | Ophthalmic solution for artificial tears |
| AU5084693A (en) * | 1993-08-20 | 1995-03-21 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| IT1270905B (it) * | 1993-10-15 | 1997-05-13 | Bruschettini Srl | Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta |
| WO1996011003A1 (en) * | 1994-10-10 | 1996-04-18 | Novartis Ag | Ophthalmic and aural compositions containing diclofenac potassium |
| IT1275434B (it) | 1995-05-19 | 1997-08-07 | Farmila Farma Milano | Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante |
| JPH0920648A (ja) * | 1995-06-30 | 1997-01-21 | Zenichi Ogita | 外用剤 |
| JPH1017488A (ja) * | 1996-06-25 | 1998-01-20 | Asahi Glass Co Ltd | 緑内障治療薬 |
| JP2001504132A (ja) * | 1997-01-29 | 2001-03-27 | エイ グレン ブラスウェル | 液体点眼剤組成物 |
| RU2114587C1 (ru) | 1997-03-27 | 1998-07-10 | Малое государственное предприятие "Научно-экспериментальное производство" | Раствор для защиты роговицы от повреждений "визитон-1" |
| JPH1171282A (ja) * | 1997-09-01 | 1999-03-16 | Senju Pharmaceut Co Ltd | 点眼用水性製剤 |
| ES2215752T3 (es) * | 1999-11-09 | 2004-10-16 | Alcon, Inc | Lipoxina a4 y analogos para el tratamiento del ojo seco. |
| AU2001236909A1 (en) * | 2000-02-11 | 2001-08-20 | Duke University | Method of treating disorders of the eye |
| RU2171107C1 (ru) | 2000-04-25 | 2001-07-27 | Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" | Глазные капли |
| US6503892B2 (en) * | 2000-04-26 | 2003-01-07 | New England Medical Center Hospitals Inc. | Method of using matrix metalloproteinase inhibitors in filtering blebs following glaucoma filtering surgery and in the treatment of ischemic damage to the retina and optic nerve |
| RU2165749C1 (ru) * | 2000-07-06 | 2001-04-27 | Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" | Способ восстановления эндотелия роговицы |
| IT1318640B1 (it) * | 2000-07-25 | 2003-08-27 | Univ Catania | Derivati di carnosina, procedimento per la loro preparazione ecomposizioni farmaceutiche che li contengono. |
| DK1347787T4 (da) * | 2001-01-09 | 2011-01-03 | Louis Johan Wagenaar | Anvendelse af dexpanthenol i kontaktlinse-plejesammensætninger |
| JP2003171276A (ja) * | 2001-11-30 | 2003-06-17 | Menicon Co Ltd | 眼精疲労改善眼科用組成物 |
| US7795203B2 (en) * | 2002-09-30 | 2010-09-14 | Babizhayev Mark A | Method for topical treatment of eye disease and composition and device for said treatment |
-
2003
- 2003-09-29 US US10/480,724 patent/US7795203B2/en active Active - Reinstated
- 2003-09-29 WO PCT/IB2003/004259 patent/WO2004028536A1/en not_active Ceased
- 2003-09-29 EP EP03748394A patent/EP1551399A4/en not_active Withdrawn
- 2003-09-29 JP JP2004539362A patent/JP2006504701A/ja active Pending
-
2010
- 2010-07-19 US US12/838,733 patent/US9044425B2/en not_active Expired - Lifetime
- 2010-07-19 US US12/839,285 patent/US20110245177A1/en not_active Abandoned
- 2010-10-18 JP JP2010233467A patent/JP2011037891A/ja active Pending
- 2010-10-18 JP JP2010233468A patent/JP2011037892A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011037891A5 (https=) | ||
| NZ588938A (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
| JP6014033B2 (ja) | 防腐剤無添加ビマトプロストおよびチモロール溶液 | |
| CA2807084C (en) | Preservative free brimonidine and timolol solutions | |
| JP2011516537A (ja) | 安定性のある眼科用の製剤 | |
| KR20140076587A (ko) | 노안, 경도 원시 및 불규칙한 난시의 치료를 위한 조성물 및 방법 | |
| JP6373278B2 (ja) | ドライアイ治療用点眼剤 | |
| CA3010279A1 (en) | Compositions for the treatment of presbyopia | |
| US11857537B2 (en) | Use of prostacyclin antagonists for treating ocular surface nociception | |
| JP2013534527A (ja) | コンタクトレンズ乳頭結膜炎及びアレルギー性眼疾患の予防及び処置のための組成物 | |
| JP2018508545A (ja) | ブリモニジン及びチモロールの固定用量合剤 | |
| AU2011282679A1 (en) | Preservative free bimatoprost solutions | |
| CA2761740A1 (en) | Phosphate-free pharmaceutical composition for the treatment of glaucoma | |
| WO2022103250A1 (es) | Composición oftalmológica sinérgica en dosis de baja concentración eficaz en la prevención, control y erradicación de la presbicia | |
| WO2013158961A1 (en) | Combination of a non-steroidal anti-inflammatory drug with an anti-histaminic drug intended for ophthalmic use | |
| Nardi | Nepafenac in the prevention and treatment of ocular inflammation and pain following cataract surgery in the prevention of post-operative macular oedema in diabetic patients | |
| JP2013129604A (ja) | 緑内障治療薬を含有する徐放性フィルム製剤 | |
| US20250127760A1 (en) | Composition and use thereof in preparation of medicament for treating presbyopia | |
| Nowroozzadeh | Prostaglandin analogs may aggravate myopic regression after laser in situ keratomileusis | |
| Ramugade et al. | Nonsteroidal Anti-inflammatory Drugs in Ophthalmology |